Table 3.

Details on MAEs in children aged 12–24 months participating in an anthelminthic trial in Peru (2011–2013)

No.	Intervention group	MAE	Study visit before MAE	Days between intervention and MAE	Intervention received before MAE
1	MEB/MEB*	Acute urticaria	Baseline	0.13	Mebendazole
2	PBO/MEB†	Emetic syndrome	Baseline	0.13	Placebo
3	PBO/PBO‡	Acute pharyngitis, urticaria	Baseline	0.25	Placebo
4	PBO/PBO	ADD	Baseline	0.25	Placebo
5	PBO/PBO	ADD with dehydration	Baseline	0.33	Placebo
6	PBO/MEB	ADD	Baseline	0.42	Placebo
7	PBO/PBO	Allergic reaction	18-month	0.42	Placebo
8	MEB/PBO§	ADD, urinary tract infection	18-month	0.46	Placebo
9	MEB/PBO	ADD	Baseline	0.5	Mebendazole
10	MEB/MEB	ADD without dehydration	Baseline	0.67	Mebendazole
11	PBO/MEB	Acute pharyngitis	Baseline	1	Placebo
12	PBO/MEB	ADD with dehydration	Baseline	1	Placebo
13	PBO/PBO	Suspected dysentery	Baseline	1	Placebo
14	MEB/PBO	ADD without dehydration	Baseline	1	Mebendazole
15	PBO/MEB	ADD with dehydration	Baseline	1	Placebo
16	MEB/MEB	ADD without dehydration	Baseline	1	Mebendazole
17	PBO/PBO	ADD with dehydration	Baseline	1	Placebo
18	MEB/MEB	ADD, bronchial hyperactivity	Baseline	1	Mebendazole
19	PBO/PBO	ADD	Baseline	2	Placebo
20	MEB/PBO	ADD	Baseline	2	Mebendazole
21	MEB/PBO	Allergic reaction	Baseline	2	Mebendazole
22	MEB/MEB	ADD without dehydration	Baseline	2	Mebendazole
23	MEB/MEB	ADD without dehydration	Baseline	2	Mebendazole
24	MEB/MEB	ADD without dehydration	Baseline	2	Mebendazole
25	MEB/MEB	ADD without dehydration	18-month	3	Mebendazole
26	MEB/MEB	Conjunctivitis	18-month	3	Mebendazole
27	PBO/MEB	Febrile syndrome	18-month	3	Mebendazole
28	PBO/MEB	Acute rhinopharyngitis	Baseline	3	Placebo
29	PBO/MEB	ADD with dehydration	Baseline	4	Placebo
30	PBO/MEB	Common cold, ADD without dehydration	Baseline	5	Placebo
31	PBO/PBO	ADD with dehydration, febrile syndrome	Baseline	6	Placebo

ADD = Acute diarrheal disease; MAE = minor adverse events.

^*Group 3 (MEB/MEB): mebendazole at the 12- and 18-month visits.

^†Group 2 (PBO/MEB): placebo at the 12-month visit and mebendazole at the 18-month visit.

^‡Group 4 (PBO/PBO): placebo at the 12- and 18-month visits.

^§Group 1 (MEB/PBO): mebendazole at the 12-month visit and placebo at the 18-month visit.